PDE4 inhibitors, which mediates cAMP breakdown (see below), are also approved to be used as an add-on treatment for severe COPD patients associated with bronchitis and a history of frequent exacerbations [69]. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.